VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Saturday, January 10, 2026
Stock Comparison
Arthur J. Gallagher & Co. vs AstraZeneca PLC
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Arthur J. Gallagher & Co.
AJG · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Arthur J. Gallagher & Co.'s moat claims, evidence, and risks.
View AJG analysisAstraZeneca PLC
AZN · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into AstraZeneca PLC's moat claims, evidence, and risks.
View AZN analysisComparison highlights
- Moat score gap: AstraZeneca PLC leads (71 / 100 vs 69 / 100 for Arthur J. Gallagher & Co.).
- Segment focus: Arthur J. Gallagher & Co. has 2 segments (86% in Brokerage); AstraZeneca PLC has 6 segments (41% in Oncology).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Moderate vs Strong.
- Moat breadth: Arthur J. Gallagher & Co. has 4 moat types across 2 domains; AstraZeneca PLC has 4 across 3.
Primary market context
Arthur J. Gallagher & Co.
Brokerage
Insurance and reinsurance brokerage and consulting
Global
Commercial, industrial, public sector, nonprofit and other organizations; underwriting enterprises for reinsurance placements
Intermediary / broker / advisor
86%
AstraZeneca PLC
Oncology
Innovator oncology therapeutics (branded prescription medicines)
Global
Hospitals, oncology clinics, payers
Innovator biopharmaceutical company
41%
Side-by-side metrics
Moat coverage
Shared moat types
Arthur J. Gallagher & Co. strengths
AstraZeneca PLC strengths
Segment mix
Arthur J. Gallagher & Co. segments
Full profile >Brokerage
Oligopoly
Risk Management
Competitive
AstraZeneca PLC segments
Full profile >Oncology
Oligopoly
Cardiovascular, Renal and Metabolism (CVRM)
Competitive
Respiratory & Immunology (R&I)
Oligopoly
Vaccines & Immune Therapies (V&I)
Oligopoly
Rare Disease
Oligopoly
Other Medicines
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.